Skip to main content
芭薇股份 logo

芭薇股份 — Investor Relations & Filings

Ticker · 920123 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 240 across all filing types
Latest filing 2024-04-25 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920123

About 芭薇股份

https://www.gzbawei.com/

Guangdong Bawei Biotechnology Corp., Ltd. is a comprehensive beauty and personal care solution provider specializing in research, development, production, and testing. The company offers integrated OEM, ODM, and OBM services, covering a wide range of product categories including skincare, hair care, body care, and makeup. Bawei is recognized for its commitment to scientific innovation, operating advanced R&D laboratories and an independent third-party testing center that ensures product safety and efficacy. By leveraging automated production lines and a rigorous quality management system, the company serves a diverse portfolio of domestic and international brands. Its core focus remains on delivering high-quality, customized formulations and manufacturing excellence to meet evolving consumer demands in the global beauty market.

Recent filings

Filing Released Lang Actions
预计公司2024 年度向银行申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Guangdong Bawei Biotechnology Co., Ltd. regarding the company's plan to apply for a comprehensive credit line from banks for the year 2024. It details the intended credit amount, types of credit, and the authorization process involving the board and shareholders. The document includes information about the board meeting resolutions and independent director opinions but does not contain actual financial statements or detailed financial results. It is a notice about financing activities and credit arrangements rather than a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short and focused on financing plans, not a report publication or regulatory filing. Confidence is high due to clear content and context.
2024-04-25 Chinese
募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the storage and actual use of raised funds by Guangdong Bawei Biotechnology Co., Ltd. It includes specifics about the fundraising event, the amount raised, the use of funds, compliance with regulations, and audit opinions. The document references regulatory guidelines and includes an auditor's verification report. The content focuses on the management and use of capital raised through a directed stock issuance, which aligns with a Capital/Financing Update. The document is not an announcement of a report but the report itself, containing substantive financial data about fundraising and fund usage. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is under 5,000 characters but contains detailed financial and regulatory information, so it is not a mere announcement or certification but a substantive report.
2024-04-25 Chinese
2023年年度报告
Annual Report Classification · 100% confidence The document is titled '年度报告' which translates to 'Annual Report' and covers the full fiscal year 2023 (2023-01-01 to 2023-12-31). It includes comprehensive sections such as company overview, financial data and indicators, management discussion and analysis, major events, shareholder information, financing and profit distribution, board and senior management details, industry information, corporate governance, internal controls, and full financial accounting reports. The document also contains audited financial statements with a standard unqualified audit opinion from an accounting firm. The length is substantial (15,000 characters), indicating it is the full report rather than an announcement. The content includes detailed financial figures, business analysis, risk factors, and other elements typical of an official annual report. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2024-04-25 Chinese
第三届董事会第二十七次会议相关事项之独立董事独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion statement related to the company's board meeting held on April 25, 2024. It discusses several agenda items including the 2023 annual report, appointment of the audit firm for 2024, use of idle funds, a special report on fundraising usage, credit line application, and insurance purchase. The document is a formal opinion and recommendation from independent directors on matters to be submitted to the shareholders' meeting. It does not contain the full annual report or financial statements itself, but rather opinions on these matters. The document length is short (1874 characters) and it serves as a board/management information announcement regarding board meeting decisions and opinions. Therefore, the appropriate classification is Board/Management Information (MANG).
2024-04-25 Chinese
关于使用闲置自有资金购买理财产品的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Guangdong Bawei Biotechnology Co., Ltd. regarding the use of idle self-owned funds to purchase financial products. It details the purpose, amount, decision-making process, risk analysis, and impact on the company. The document is a formal announcement about financing activities related to cash management and investment of idle funds, not a financial report or audit. It does not contain financial statements or earnings data. The content fits the category of Capital/Financing Update (CAP) as it relates to the company's financing activities and capital management.
2024-04-25 Chinese
对外投资管理办法
Governance Information Classification · 95% confidence The document is titled as "广东芭薇生物科技股份有限公司对外投资管理办法" which translates to "Guangdong Bawei Biotechnology Co., Ltd. External Investment Management Measures." It is a detailed internal policy document outlining the company's procedures, principles, and governance related to external investments. It includes sections on approval authorities, organizational management, decision-making processes, financial management, and auditing related to investments. The document is not a financial report, earnings release, or announcement of voting results. It is not a regulatory filing or a brief announcement but a comprehensive internal governance document. It does not contain financial statements or earnings data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a presentation or call transcript. The document is a governance-related policy document detailing internal rules and procedures for investment management. Therefore, the most appropriate classification is Governance Information (CGR).
2024-04-25 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.